Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-04-24

Clinical Trial Update: Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating dual-targeting CAR-NK cells for recurrent/progressive glioblastoma and high-grade gliomas is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dual-targeting CAR-NK cells (CAR-NK cells)

Snippet

Sponsor: Beijing Biotech | Conditions: Malignant Glioma, High-Grade Gliomas | Phase 1 | Status: RECRUITING